Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
Haruko ShimaAkiko KadaAkihiko TanizawaIori SatoChikako TonoMasaki ItoYuki YuzaAkihiro WatanabeKiyoko KamibeppuHideko UryuKatsuyoshi KohChihaya ImaiNao YoshidaYuhki KogaNaoto FujitaAkiko M SaitoSouichi AdachiEiichi IshiiHiroyuki ShimadaPublished in: Pediatric blood & cancer (2022)
TKI could be discontinued safely in patients with pediatric CML showing a sustained deep MR.